GlaxoSmithKline Operating Margin from 2010 to 2025

GSK Stock  USD 38.36  1.28  3.45%   
GlaxoSmithKline PLC Operating Profit Margin yearly trend continues to be quite stable with very little volatility. Operating Profit Margin may rise above 0.32 this year.
Check GlaxoSmithKline PLC financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among GlaxoSmithKline PLC's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.8 B, Interest Expense of 502.2 M or Total Revenue of 19.9 B, as well as many indicators such as Price To Sales Ratio of 2.12, Dividend Yield of 0.0451 or PTB Ratio of 8.65. GlaxoSmithKline financial statements analysis is a perfect complement when working with GlaxoSmithKline PLC Valuation or Volatility modules.
  
Check out the analysis of GlaxoSmithKline PLC Correlation against competitors.

Latest GlaxoSmithKline PLC's Operating Margin Growth Pattern

Below is the plot of the Operating Profit Margin of GlaxoSmithKline PLC ADR over the last few years. It is GlaxoSmithKline PLC's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in GlaxoSmithKline PLC's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 0.17 %10 Years Trend
Pretty Stable
   Operating Profit Margin   
       Timeline  

GlaxoSmithKline Operating Margin Regression Statistics

Arithmetic Mean0.24
Geometric Mean0.23
Coefficient Of Variation38.76
Mean Deviation0.07
Median0.23
Standard Deviation0.09
Sample Variance0.01
Range0.34
R-Value(0.26)
Mean Square Error0.01
R-Squared0.07
Significance0.33
Slope(0.01)
Total Sum of Squares0.13

GlaxoSmithKline Operating Margin History

2025 0.32
2024 0.26
2022 0.22
2020 0.23
2019 0.21
2018 0.18
2017 0.14

About GlaxoSmithKline PLC Financial Statements

GlaxoSmithKline PLC investors utilize fundamental indicators, such as Operating Margin, to predict how GlaxoSmithKline Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. Gsk Plc is traded on New York Stock Exchange in the United States.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether GlaxoSmithKline PLC ADR is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GlaxoSmithKline Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glaxosmithkline Plc Adr Stock. Highlighted below are key reports to facilitate an investment decision about Glaxosmithkline Plc Adr Stock:
Check out the analysis of GlaxoSmithKline PLC Correlation against competitors.
You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.167
Dividend Share
0.61
Earnings Share
1.53
Revenue Per Share
15.392
Quarterly Revenue Growth
0.008
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.